Viela Bio, Inc. IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Viela Bio, Inc., and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Viela Bio, Inc. | VIE - NASDAQ |
$19.00-$21.00 | $19.00 | $21.50 | 7.9 million | 10/3/2019 |
| Goldman Sachs, Morgan Stanley, Cowen | ||||||
Co-Manager(s): Guggenheim Securities | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-08-29 Terms Added 2019-09-23 | ||||||
Viela Bio, Inc. Quote & Chart - Click for current quote - VIE
IPO Boutique aggregates information on public companies and private companies, such as "VIE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Viela Bio, Inc. (adapted from Viela Bio, Inc. prospectus):
They are a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, which we collectively refer to as autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, which we collectively refer to as autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "VIE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.